Abstract

Questioning the Design of Non-Inferiority Trials: The Strange Case for Therapeutic Drug Monitoring Absence in Phase III Trials.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call